The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of pazopanib (P) combined with bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors.
Sylvie Negrier
Honoraria - Novartis; Pfizer
Research Funding - GlaxoSmithKline; Roche
David Pérol
Honoraria - Roche
Rastilav Bahleda
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Etienne Chatelut
No relevant relationships to disclose
Helen Jane Boyle
No relevant relationships to disclose
Philippe A Cassier
No relevant relationships to disclose
Celine Ferlay
No relevant relationships to disclose
Severine Metzger
No relevant relationships to disclose
Ellen Blanc
No relevant relationships to disclose
Jean-Charles Soria
Honoraria - Roche
Bernard J. Escudier
Consultant or Advisory Role - AVEO (U); Bayer; GlaxoSmithKline; Novartis; Pfizer